Who's Attending?

Accelerate the Clinical Translation of CAR-T, Treg & MSC-Based Therapies with Improved Efficacy, Durability & Safety to Revolutionize Curative Care for Chronic Autoimmune Disease

November 28-30, 2023 | Philadelphia, PA

AutoImmune - Industry News Banner - NEW

Join the Inaugural Cell Therapy for Autoimmune Disease Summit!

Amidst the transformative impact of CAR-T and other cell therapies in cancer treatment, there is an electrifying sense of anticipation for their immense potential in indications beyond oncology. With compelling clinical results demonstrated in lupus, multiple sclerosis, pemphigus vulgaris, and many other autoimmune diseases, a wave of optimism surges forward. Moreover, the FDA’s rapid issuance of IND approvals and fast-track designations adds to the momentum of this groundbreaking approach, underscoring its potential to revolutionize the lives of millions affected by chronic autoimmune diseases worldwide. 

Enter the inaugural Cell Therapy for Autoimmune Disease Summit, a pioneering platform singularly focused on uniting and empowering this community for the first time. Here, experts delve into cutting-edge frontiers of pre-clinical, translational, and clinical advancements encompassing all cell-based therapies, including CAR-T, Treg, and MSC, with the shared objective of developing better therapies for patients with chronic autoimmune diseases.  

The World-Class Speaker Faculty Includes:

What Our Speakers Have to Say:

“After oncology, autoimmune disorders are the next logical step in the development of CAR T-cell and other cellular therapies. Hanson Wade has managed to bring together all the relevant experts in this developing field for an exciting few days.”

- Miloš Miljković, Chief Medical Officer, Cartesian Therapeutics 

“It is a new step forward seeing cell therapies extend their reach in helping patients with autoimmune disease. Having a forum put on by Hanson Wade to discuss how to optimize their effectiveness will be insightful to say the least.”

Jeff Liter, Chief Executive Officer, Luminary Therapeutics 

“We are at the dawn of the exciting exploration of cell therapy for the treatment of autoimmune diseases.  This novel approach to treatment has the potential to substantially positively impact the lives of patients with a variety of different systemic autoimmune diseases.  This summit will bring together academic investigators and biopharmaceutical collaborators to discuss this rapidly evolving topic.”

- Peter Merkel, Chief, Division of Rheumatology & Professor, Medicine & Epidemiology, University of Pennsylvania